Drug intelligence / Profile preview

Kover-All

Development stage: Unknown
Lead developer: Anglo-French Drugs & Industries
Modality: Small Molecules, Peptides
Administration: Oral

Overview

Kover-All is an oral nutraceutical supplement developed and marketed by Anglo-French Drugs & Industries. It is formulated as a multi-ingredient tablet designed to support joint and bone health, specifically targeting conditions such as osteoarthritis, bone weakness, cartilage degeneration, collagen degradation, and muscle injuries. The supplement contains a combination of active ingredients, including glucosamine sulfate, chondroitin sulfate, rosehip extract, curcuminoids, collagen peptide type II, sodium hyaluronate, vitamin C, vitamin E, and selenium. Together, these components work synergistically to stimulate cartilage production, provide anti-inflammatory and antioxidant protection, increase bone flexibility, and soothe muscle injuries.

Brand names: Kover-All
Other names: Kover AllKover-All Tablets

Beyond the preview

Go deeper on Kover-All.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kover-All.